Rene Gonzalez

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma
    Sanjiv S Agarwala
    Melanoma Center, University of Pittsburgh Cancer Institute, 200 Lothrop Street, Pittsburgh, PA 15213 2582, USA
    J Clin Oncol 20:125-33. 2002
  2. pmc Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report
    Guillermo A Escobar
    Department of Surgery, Division of GI, Tumor and Endocrine Surgery, University of Colorado Health Sciences Center, 4200 E, 9th Ave, Denver, CO 80262, USA
    BMC Cancer 7:13. 2007
  3. ncbi request reprint Phase 2 trial of Allovectin-7 in advanced metastatic melanoma
    Rene Gonzalez
    University of Colorado Cancer Center, Aurora, CO 80010 5010, USA
    Melanoma Res 16:521-6. 2006
  4. pmc A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes
    Nicole Kounalakis
    Division of GI, Tumor and Endocrine Surgery, University of Colorado Medical Center, Aurora, CO, USA
    Immunotherapy 4:679-86. 2012
  5. ncbi request reprint Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma
    Karl D Lewis
    University of Colorado Health Sciences Center, Aurora, CO, USA
    J Clin Oncol 24:3157-63. 2006
  6. pmc ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets
    Yuchun Luo
    Department of Dermatology, University of Colorado Denver, Aurora, Colorado 80045, USA
    Stem Cells 30:2100-13. 2012
  7. pmc Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance
    Yuchun Luo
    Department of Dermatology, University of Colorado Denver, Aurora, Colorado 80045, USA
    J Invest Dermatol 132:2440-50. 2012
  8. pmc Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result
    Edward L Jones
    Department of Surgery, University of Colorado Denver, Aurora, CO 80045, USA
    JAMA Surg 148:456-61. 2013
  9. doi request reprint A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma
    Karl D Lewis
    University of Colorado Health Sciences Center, Aurora, CO, USA
    Invest New Drugs 29:161-6. 2011
  10. doi request reprint Immunologic therapy targeting metastatic melanoma: allovectin-7
    Rozina Chowdhery
    University of Colorado Cancer Center, Anshutz Cancer Pavilion, PO Box 6510, Mail Stop F 703, Aurora, CO 80045, USA
    Immunotherapy 3:17-21. 2011

Detail Information

Publications38

  1. ncbi request reprint Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma
    Sanjiv S Agarwala
    Melanoma Center, University of Pittsburgh Cancer Institute, 200 Lothrop Street, Pittsburgh, PA 15213 2582, USA
    J Clin Oncol 20:125-33. 2002
    ..This study was designed to determine whether the addition of histamine to a subcutaneous (SC) regimen of interleukin-2 (IL-2) would improve the survival of metastatic melanoma patients...
  2. pmc Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report
    Guillermo A Escobar
    Department of Surgery, Division of GI, Tumor and Endocrine Surgery, University of Colorado Health Sciences Center, 4200 E, 9th Ave, Denver, CO 80262, USA
    BMC Cancer 7:13. 2007
    ..It tends to present in large or metastatic tumors, and can appear at any time in the progression of the disease. We present herein a case of NICTH in a GIST tumor and report an exon 9 mutation associated to it...
  3. ncbi request reprint Phase 2 trial of Allovectin-7 in advanced metastatic melanoma
    Rene Gonzalez
    University of Colorado Cancer Center, Aurora, CO 80010 5010, USA
    Melanoma Res 16:521-6. 2006
    ..8 months median duration of response. Allovectin-7 was shown to be safe and exhibit biological activity at this dose. Its safety profile may enable Allovectin-7 to be used at higher doses, which may provide greater clinical activity...
  4. pmc A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes
    Nicole Kounalakis
    Division of GI, Tumor and Endocrine Surgery, University of Colorado Medical Center, Aurora, CO, USA
    Immunotherapy 4:679-86. 2012
    ..Completion lymph node dissection (CLND) and adjuvant therapy are recommended for node-positive melanoma patients. We sought to analyze our institution's experience with neoadjuvant biochemotherapy in stage III patients...
  5. ncbi request reprint Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma
    Karl D Lewis
    University of Colorado Health Sciences Center, Aurora, CO, USA
    J Clin Oncol 24:3157-63. 2006
    ..To determine the relapse-free survival, overall survival, and response rate of patients with stage III melanoma treated with neoadjuvant biochemotherapy in a multicenter setting...
  6. pmc ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets
    Yuchun Luo
    Department of Dermatology, University of Colorado Denver, Aurora, Colorado 80045, USA
    Stem Cells 30:2100-13. 2012
    ..Further investigation of these isozymes and genes will enhance our understanding of the molecular mechanisms governing CSCs and reveal new molecular targets for therapeutic intervention of cancer...
  7. pmc Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance
    Yuchun Luo
    Department of Dermatology, University of Colorado Denver, Aurora, Colorado 80045, USA
    J Invest Dermatol 132:2440-50. 2012
    ..To our knowledge, this is a previously unreported study to isolate SP cells from melanoma patients and to investigate the gene expression profiling of these cells...
  8. pmc Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result
    Edward L Jones
    Department of Surgery, University of Colorado Denver, Aurora, CO 80045, USA
    JAMA Surg 148:456-61. 2013
    ..To analyze the predictors and patterns of recurrence of melanoma in patients with a negative sentinel lymph node biopsy result...
  9. doi request reprint A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma
    Karl D Lewis
    University of Colorado Health Sciences Center, Aurora, CO, USA
    Invest New Drugs 29:161-6. 2011
    ..YM155 is a small molecule suppressant of survivin that has been shown in preclinical cell lines, xenograft models and phase I studies to have anti-tumor activity...
  10. doi request reprint Immunologic therapy targeting metastatic melanoma: allovectin-7
    Rozina Chowdhery
    University of Colorado Cancer Center, Anshutz Cancer Pavilion, PO Box 6510, Mail Stop F 703, Aurora, CO 80045, USA
    Immunotherapy 3:17-21. 2011
    ..Currently, a Phase III trial has completed enrollment and is set to determine the safety and efficacy of treatment in comparison with standard chemotherapy...
  11. ncbi request reprint Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin
    F Stephen Hodi
    F Stephen Hodi, Anita Giobbie Hurder, Philip Friedlander, Jason J Luke, Katherine A Zukotynski, Jeffrey T Yap, Annick D Van den Abbeele, and George D Demetri, Dana Farber Cancer Institute Jonathan A Fletcher, Meijun Zhu, and Adrian Marino Enriquez, Brigham and Women s Hospital Donald Lawrence, Keith T Flaherty, and David E Fisher, Massachusetts General Hospital, Boston, MA Christopher L Corless, Michael C Heinrich, and Carol Beadling, Portland Veterans Administration Medical Center and Oregon Health and Science University, Portland, OR Philip Friedlander, Mount Sinai Medical Center, New York, NY Rene Gonzalez, University of Colorado Cancer Center, Aurora, CO Jeffrey S Weber, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Thomas F Gajewski, University of Chicago, Chicago, IL Steven J O Day, Beverly Hills Cancer Center, Beverly Hills, Office of Analysis and Epidemiology
    J Clin Oncol 31:3182-90. 2013
    ..Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeutic opportunities...
  12. pmc Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control
    Michelle A Stinauer
    University of Colorado Denver, School of Medicine, Aurora, Colorado, USA
    Radiat Oncol 6:34. 2011
    ..Whereas stereotactic body radiation therapy (SBRT) involves radiation dose intensification via escalation, we hypothesize SBRT might result in similar high local control rates as previously published on metastases of varying histologies...
  13. doi request reprint Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature
    Mayumi Fujita
    Department of Dermatology and Division of Medical Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado 80010 7163, USA
    Int J Dermatol 48:426-30. 2009
    ..The development of vitiligo has been associated with an improved clinical response in melanoma patients...
  14. pmc ABT-737 synergizes with Bortezomib to kill melanoma cells
    Steven N Reuland
    University of Colorado Denver, School of Medicine, Department of Dermatology, Aurora, CO 80045, USA
    Biol Open 1:92-100. 2012
    ..These data imply that less toxic drugs fulfilling a function similar to Bortezomib to neutralize Mcl-1 are promising candidates for combination with ABT-737 for treating melanomas...
  15. doi request reprint Novel therapies in melanoma
    Benjamin Scheier
    Box B177, 1665 Aurora Court, Aurora, Colorado 80045, USA
    Immunotherapy 3:1461-9. 2011
    ....
  16. ncbi request reprint Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma
    Michael Bergen
    University of Colorado Cancer Center, Anschutz Cancer Pavilion, PO Box 6510, Mail Stop F 703, Aurora, Colorado 80010, USA
    Expert Opin Biol Ther 3:377-84. 2003
    ..Ongoing trials are further investigating potential clinical uses of Allovectin-7...
  17. doi request reprint Increased survival from stage IV melanoma associated with fewer regulatory T Cells
    Joel M Baumgartner
    Department of Surgery, University of Colorado Denver, Denver, Colorado 80262, USA
    J Surg Res 154:13-20. 2009
    ..In this study, markers of immune escape including regulatory T cells (T(regs)), dendritic cells (DCs), and TGF-beta were evaluated in 14 Stage IV melanoma patients and correlated with survival...
  18. ncbi request reprint Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma
    Nathan W Pearlman
    Department of Surgery, University of Colorado Health Science, C311, University Hospital, 4200 E Ninth Avenue, Denver, CO 80262, USA
    Am J Surg 192:878-81. 2006
    ..We hypothesized SLN metastatic size of < or =2 mm would predict CLND status and prognosis...
  19. ncbi request reprint Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients
    Martin D McCarter
    Department of Surgery, University of Colorado at Denver Health Sciences Center, Denver, CO 80262, USA
    Ann Surg Oncol 14:2854-60. 2007
    ..Regulatory T cells (T(regs)) and plasmacytoid subpopulations of dendritic cells (pDCs) inhibit the immune response. We hypothesize that melanoma upregulates T(regs )and subpopulations of immunosuppressive dendritic cells (DCs)...
  20. ncbi request reprint A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma
    Karl D Lewis
    University of Colorado, Cancer Center, 1665 North Ursula St, Mail Stop F 703, Aurora, CO 80045, USA
    Invest New Drugs 24:89-94. 2006
    ..In conclusion, Apomine, at the current dose studied, failed to produce a 30% progression free survival rate at 16 weeks considered to be a meaningful benefit for further development...
  21. ncbi request reprint A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma
    Karl D Lewis
    Cutaneous Oncology Program, University of Colorado Health Sciences Center, PO Box 6510, Mail Stop F703, Aurora, CO 80045, USA
    Invest New Drugs 26:89-94. 2008
    ..Although the current study did not meet the primary end-point of progression free survival of >or=20%, there is some evidence of activity and further investigation is warranted...
  22. ncbi request reprint PI-88: a novel inhibitor of angiogenesis
    Ragini Kudchadkar
    University of Colorado Cancer Center, Aurora, CO 80045, USA
    Expert Opin Investig Drugs 17:1769-76. 2008
    ..However, the development of antibody-induced thrombocytopenia has limited its use in some patients...
  23. ncbi request reprint A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF
    Karl D Lewis
    University of Colorado Cancer Center, Aurora, Colorado, USA
    Cancer Invest 23:303-8. 2005
    ..6 months. Further studies of this novel biochemotherapy regimen are not indicated. Other schedules that incorporate temozolomide and/or GM-CSF and further studies to define the optimal method of delivering IL-2 should be pursued...
  24. ncbi request reprint Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass
    Karl D Lewis
    Division of Medical Oncology, Cutaneous Oncology Program, University of Colorado Cancer Center, Denver, Colorado, USA
    Oncology (Williston Park) 20:763-70. 2006
  25. ncbi request reprint A case of Merkel cell carcinoma
    Ragini Kudchadkar
    Department of Cutaneous Oncology, University of Colorado at Denver Health Sciences Center, Aurora, Colorado 80045, USA
    Oncology (Williston Park) 22:322-8. 2008
  26. pmc Therapeutic options in cutaneous melanoma: latest developments
    Rodabe N Amaria
    Department of Hematology Oncology, University of Colorado at Denver, Aurora, Colorado, USA
    Ther Adv Med Oncol 3:245-51. 2011
    ..Thus, this is a new era in the management of melanoma and we review the recent progress made in treating patients with advanced disease...
  27. ncbi request reprint A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma
    A Scott Pierson
    University of Colorado Cancer Center, Division of Medical Oncology, Anshutz Cancer Pavilion, Aurora 80010 0510, USA
    Invest New Drugs 20:357-62. 2002
    ..Based upon these data, Irofulven does not demonstrate significant antitumor activity to warrant further investigation in advanced melanoma...
  28. ncbi request reprint A phase II study of neoadjuvant biochemotherapy for stage III melanoma
    Peter Gibbs
    Oncology Department, Royal Melbourne Hospital, Parkville, Victoria, Australia
    Cancer 94:470-6. 2002
    ..Phase II studies of biochemotherapy (combining interleukin-2, interferon-alpha, and multiagent chemotherapy) have reported high response rates and a significant number of durable complete responses in patients with metastatic melanoma...
  29. ncbi request reprint A young woman with melanoma diagnosed during pregnancy
    Karl D Lewis
    Oncology (Williston Park) 18:794-9. 2004
  30. ncbi request reprint Identifying risk factors for complications following sentinel lymph node biopsy for melanoma
    J Brent Roaten
    Department of Surgery and Medical Oncology, University of Colorado Health Sciences Center, Denver 80220, USA
    Arch Surg 140:85-9. 2005
    ..However, little information is available to refute or support this assumption...
  31. ncbi request reprint Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents
    J Brent Roaten
    Department of Surgery, University of Colorado Health Science Center, Denver, CO 80262, USA
    J Pediatr Surg 40:232-5. 2005
    ..The goal of this study was to determine outcomes and complications of children and adolescent patients undergoing SLNBX at the authors' institution...
  32. ncbi request reprint Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma
    Robert W Weber
    Northern California Melanoma Center, Saint Francis Memorial Hospital, 900 Hyde St, San Francisco, CA 94109, USA
    J Clin Oncol 23:8992-9000. 2005
    ..The objective of this study was to further investigate the efficacy and safety of low-dose outpatient chemobiotherapy in patients with unresectable metastatic melanoma...
  33. ncbi request reprint Survival in sentinel lymph node-positive pediatric melanoma
    J Brent Roaten
    Department of Surgery, University of Colorado Health Science Center, Denver, CO 80262, USA
    J Pediatr Surg 40:988-92; discussion 992. 2005
    ..Sentinel lymph node (SLN) status is the strongest predictor of survival in adult melanoma. However, the prognostic value of SLN status in children and adolescents with melanoma is unknown...
  34. ncbi request reprint Metastatic melanoma in the breast: a report of 27 cases
    Larisa Ravdel
    Division of Medical Oncology, University of Colorado Health Science Center, Denver, Colorado 80262, USA
    J Surg Oncol 94:101-4. 2006
    ..Melanoma is, however, among the most commonly reported primary tumors to metastasize to the breast. With the increasing incidence of melanoma, this complication is being encountered with greater frequency...
  35. pmc Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial
    Kazuo Koyanagi
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 23:8057-64. 2005
    ....
  36. pmc Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients
    Kazuo Koyanagi
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Clin Cancer Res 12:1137-43. 2006
    ....
  37. doi request reprint Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
    David F McDermott
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS 159, Boston, MA, USA
    J Clin Oncol 26:2178-85. 2008
    ..This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma...
  38. ncbi request reprint Lymphangiomatosis masquerading as metastatic melanoma
    William Qutub
    Department of Surgery, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Am Surg 72:367-70. 2006
    ..Diagnosis and management of lymphangiomatosis is clinically challenging. This report reviews the literature on the pathology, diagnostic imaging, and management of lymphangiomatosis...